Glaukos’ Epioxa allows cross-linking therapy for keratoconus without requiring an incision. The biotech expects to launch the ...

Rybelsus can now be used as a primary or secondary prevention pill to lower the risk of major adverse cardiovascular events ...

Ivonescimab’s progression-free survival data in non-small cell lung cancer bode well for an upcoming overall survival readout ...

Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but the fight against the disease must ...

Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma's ...

After a chaotic year that has seen the attrition of over half the FDA’s senior leadership, many of these individuals have ...

The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...

Last month, investors' hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future. Now, the regulator has accepted a refiled application after all.

Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s ...

Under the terms of the deal, Gilead will put down $120 million in an upfront payment and will promise up to $1.52 billion in ...

CMS Administrator Mehmet Oz clarified that a deal has not yet been sealed with the manufacturer of semaglutide, Novo Nordisk, ...